Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the...
Cancer
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in...
Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers
Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in...
CNS Pharmaceuticals Announces CEO Transition
Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer HOUSTON, TX / ACCESS Newswire / December 17,...
Landmark Study Shows Combination of Castle Biosciences’ DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests...
Tango Therapeutics to Participate in 44th Annual J.P. Morgan Healthcare Conference
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and...
Secura Bio Announces NCCN® Duvelisib (COPIKTRA®) Update to Clinical Practice Guidelines in Oncology for Cutaneous T-Cell Lymphoma (CTCL), Including Mycosis Fungoides and Sézary Syndrome
BERKELEY HEIGHTS, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes...
Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California
VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),...
Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering
THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG...
BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or...
numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System
AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing...
numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System
AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing...
numares Health enters ASEAN region with regulatory approval in Malaysia and first contract win for AXINON® LDLp Test System
AXINON® LDLp Test System receives Medical Device Authority (MDA) in Malaysianumares Health appoints BioD Medica for local distribution MDA filing...
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need
IRVING, Texas, Dec. 16, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision...
Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need
IRVING, Texas, Dec. 16, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision...
Utah Cancer Specialists Partners with Canopy for Remote Therapeutic Monitoring and Enterprise AI
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Canopy, the leader in Enterprise AI for oncology, today announced a partnership with...
Utah Cancer Specialists Partners with Canopy for Remote Therapeutic Monitoring and Enterprise AI
NEW YORK, Dec. 16, 2025 /PRNewswire/ -- Canopy, the leader in Enterprise AI for oncology, today announced a partnership with...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...
Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer
Regulatory submission marks a significant milestone as the Company advances toward Phase 2/3 trial initiation in Q2 2026 at full...